diagnostics

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and OthersA Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2…

1 month ago
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in BengaluruCrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and…

2 months ago
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in BengaluruCrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and…

2 months ago
Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer RiskEffective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…

2 months ago
Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solutionRoche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solution

Roche transforms mass spectrometry diagnostics with launch of cobas Mass Spec solution

December 18, 2024 01:00 ET  | Source: F. Hoffmann-La Roche Ltd Roche launches its cobas® Mass Spec solution, bringing mass…

3 months ago
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo FacilityCo-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event…

3 months ago
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo FacilityCo-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event…

3 months ago
LearnEV+ and CarTechIQ Launch GlobalTechIQ to Transform Heavy-Duty Diagnostics with AILearnEV+ and CarTechIQ Launch GlobalTechIQ to Transform Heavy-Duty Diagnostics with AI

LearnEV+ and CarTechIQ Launch GlobalTechIQ to Transform Heavy-Duty Diagnostics with AI

WYLIE, Texas and LEXINGTON, Ky., Nov. 22, 2024 (GLOBE NEWSWIRE) -- LearnEV+ and CarTechIQ have joined forces to launch GlobalTechIQ,…

4 months ago
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for TrachomaApprox. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma

Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma

TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…

4 months ago
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for TrachomaApprox. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma

Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma

TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…

4 months ago
Show more Posts